NCT07422337Recruiting
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are: * Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL/Ly who have received blinatumomab. * To determine whether revaccination in participants with non-protective titers leads to restored humoral immunity. Researchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 13 Feb 2026
- Start date
- 13 Jan 2026
- Primary completion date
- 31 Jan 2028
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- NCT number
- NCT07422337
What you commit to
- Study type: Observational
- Planned participants: 300
- From 13 Jan 2026 to the primary completion date, 31 Jan 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received or will require a bone marrow transplant and/or cellular therapy
Other illness
- Relapsed/refractory disease at any time
Other
- Pregnancy
Who the study is looking for
- Diagnosis of B-lineage acute lymphoblastic leukemia/lymphoma
- ≥1 year old and up to 21 years old at diagnosis
- Informed consent provided, and if applicable, child assent provided
- Must have received all vaccinations routinely administered during first year of life
Age in the registry: 1 year to 23 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Arkansas Children's Coordinator of this site? Confirm its status | Little Rock | United States | Recruiting |
| Arkansas Children's Northwest Coordinator of this site? Confirm its status | Springdale | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.